Latest news about Vivanza Biosciences
Vivanza Biosciences
1.94
+0.11(+6.01%)
Company Performance:
View Company Insights1D+6.01%
1M-4.90%
6M-25.67%
1Y-7.18%
5Y-69.40%
More news about Vivanza Biosciences
09Apr 26
Vivanza Biosciences Limited Confirms Non-Applicability of Large Corporate Status for FY26 Compliance
Vivanza Biosciences Limited has confirmed to BSE Limited that it does not qualify as a "Large Corporate" under regulatory criteria as of March 31, 2026. This status exempts the company from filing Initial Disclosure requirements under Annexure A and Annexure XII A for FY26, as mandated by various SEBI and BSE circulars related to debt securities fund raising by large corporates.
07Apr 26
Vivanza Biosciences Submits SEBI Confirmation Certificate for Q4 FY26
Vivanza Biosciences Limited submitted its confirmation certificate under SEBI Regulation 74(5) for Q4 FY26 to BSE Limited on April 7, 2026. The certificate, issued by Registrar and Transfer Agent Purva Sharegistry (I) Private Limited, covers the quarter ended March 31, 2026. The dematerialization report shows no share certificates were processed during the period from January 1, 2026 to March 31, 2026, with all entries marked as 'NIL'.
17Mar 26
Vivanza Biosciences Director Hemant Parikh Resigns Due to Personal Reasons
Vivanza Biosciences Limited formally announced the resignation of Mr. Hemant Amrish Parikh as Non-Executive Director, effective from close of business hours on March 17, 2026. The resignation was attributed to personal reasons with confirmation that no material concerns exist beyond those stated, ensuring full regulatory compliance under SEBI Listing Obligations.
18Dec 25
Vivanza Biosciences Formalizes MOA Amendment for Packaging Business Expansion
Vivanza Biosciences has officially informed BSE about the approved amendment to its Memorandum of Association for expanding into plastic polymer films and packaging materials manufacturing. The company received overwhelming 99.90% shareholder approval through postal ballot, enabling diversification from biosciences into comprehensive packaging solutions including PE/PP bags, paper bags, and flexible packaging materials for various industries.
11Nov 25
Vivanza Biosciences Reports Q2 Results, Appoints New Company Secretary, Plans Business Expansion
Vivanza Biosciences Limited announced key developments in its board meeting on November 11, 2025. The company reported Q2 FY2026 revenue of Rs. 373.18 lacs and profit before tax of Rs. 48.06 lacs. CS Chaitra Arora was appointed as the new Company Secretary and Compliance Officer, replacing CS Siddhi Shah who resigned. The board proposed expanding the business to include manufacturing of plastic polymer films, plastic bags, paper bags, and flexible packaging materials. A postal ballot process has been initiated for shareholder approval of the proposed changes to the Memorandum of Association.
28Oct 25
Vivanza Biosciences Promoter Reduces Stake by 3.07% Through Market Transaction
Parth H. Parikh, a promoter of Vivanza Biosciences Limited, sold 12,28,781 shares (3.07% of total share capital) in an on-market transaction on October 29, 2024. This reduced his shareholding from 31.58% to 28.50%. The company's total equity share capital stands at 40,000,000 shares with a face value of Rs. 1 per share.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,878.20
(+0.81%)
6,760.50
(-2.33%)
4,405.70
(+0.04%)
1,432.10
(-0.32%)
1,336.70
(+2.54%)
2,276.20
(+0.80%)
2,503.00
(+1.66%)
1,011.70
(+2.02%)
1,511.80
(+0.06%)
1,323.60
(+0.62%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
